Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care 2018;41:1672-1680.
Ritzel R, Harris SB, Baron H, Florez H, Roussel R, Espinasse M, Muehlen-Bartmer I, Zhang N, Bertolini M, Brulle-Wohlhueter C, Munshi M, Bolli GB. Ritzel R, et al. Among authors: espinasse m. Diabetes Care. 2019 Aug;42(8):1604. doi: 10.2337/dc19-er08. Epub 2019 Jun 21. Diabetes Care. 2019. PMID: 31227584 Free PMC article. No abstract available.
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. Home PD, et al. Among authors: espinasse m. Diabetes Obes Metab. 2018 Jan;20(1):121-128. doi: 10.1111/dom.13048. Epub 2017 Aug 8. Diabetes Obes Metab. 2018. PMID: 28661585 Free PMC article. Clinical Trial.
A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study.
Ritzel R, Harris SB, Baron H, Florez H, Roussel R, Espinasse M, Muehlen-Bartmer I, Zhang N, Bertolini M, Brulle-Wohlhueter C, Munshi M, Bolli GB. Ritzel R, et al. Among authors: espinasse m. Diabetes Care. 2018 Aug;41(8):1672-1680. doi: 10.2337/dc18-0168. Epub 2018 Jun 12. Diabetes Care. 2018. PMID: 29895556 Clinical Trial.
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Aroda VR, Frias JP, Ji L, Niemoeller E, Nguyên-Pascal ML, Denkel K, Espinasse M, Guo H, Baek S, Choi J, Lingvay I. Aroda VR, et al. Among authors: espinasse m. Diabetes Obes Metab. 2023 Aug;25(8):2084-2095. doi: 10.1111/dom.15079. Epub 2023 Apr 26. Diabetes Obes Metab. 2023. PMID: 37013892
Frailty and health-related life quality in long-term follow up of intensive care patients above 65 years old: Protocol for a Norwegian prospective, observational multicenter study.
Kroken BA, Bergum D, Berg KS, Espinasse M, Fossum OK, Garratt AM, Klepstad P, Kvåle R, Strand B, Flaatten HK, Frisvold SK. Kroken BA, et al. Among authors: espinasse m. Acta Anaesthesiol Scand. 2024 Nov;68(10):1595-1600. doi: 10.1111/aas.14532. Epub 2024 Oct 1. Acta Anaesthesiol Scand. 2024. PMID: 39353584
Human anti-smallpox long-lived memory B cells are defined by dynamic interactions in the splenic niche and long-lasting germinal center imprinting.
Chappert P, Huetz F, Espinasse MA, Chatonnet F, Pannetier L, Da Silva L, Goetz C, Mégret J, Sokal A, Crickx E, Nemazanyy I, Jung V, Guerrera C, Storck S, Mahévas M, Cosma A, Revy P, Fest T, Reynaud CA, Weill JC. Chappert P, et al. Among authors: espinasse ma. Immunity. 2022 Oct 11;55(10):1872-1890.e9. doi: 10.1016/j.immuni.2022.08.019. Epub 2022 Sep 20. Immunity. 2022. PMID: 36130603 Free PMC article.
26 results